Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 2/20 | 0.33 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7668652 | 0.87 | TAAR1 (0.39) | KCNH2CYP2A6TAAR1CHKAIDO1 | |
| SCHEMBL715204 | 0.87 | KCNH2 (0.41) | KCNH2CYP2A6TAAR1TDP1ALOX15 | |
| SCHEMBL7672662 | 0.78 | CYP1A2 (0.41) | KCNH2CYP1A2CYP2A6TAAR1CHKA | |
| SCHEMBL258549 | 0.76 | TSHR (0.32) | TAAR1 | |
| SCHEMBL8478011 | 0.75 | TDP1 (0.33) | TDP1 | |
| SCHEMBL9978976 | 0.74 | IDO1 (0.34) | KCNH2CYP1A2CYP2A6TAAR1IDO1 | |
| SCHEMBL10626556 | 0.73 | TSHR (0.36) | CYP1A2CYP2A6 | |
| SCHEMBL819968 | 0.73 | SKP2 (0.35) | KCNH2 | |
| SCHEMBL7674770 | 0.73 | TAAR1 (0.51) | TAAR1IDO1HRH3DAO | |
| SCHEMBL143961 | 0.72 | CYP1A2 (0.68) | KCNH2CYP1A2CYP2A6TAAR1CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118101-B1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-09-26 | — | — | EP | disclosed |
| US-7803810-B2 | Inhibitors | PROBIODRUG AG (DE) | 2010-09-28 | — | — | US | disclosed |
| EP-2118101-A1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2009-11-18 | — | — | EP | disclosed |
| US-20080234313-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2008-09-25 | — | — | US | disclosed |
| WO-2008110523-A1 | IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234313-A1 | NOVEL INHIBITORS | SF3A1, HBS1L, SF3A3 | KCNH2 1506/4885CYP1A2 680/4885CYP2A6 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.